Pacific Edge Limited announced that it had substantially completed a commercial agreement with Te Whatu Ora - Southern for the use of its non-invasive Cxbladder genomic biomarker tests. At this stage the contract remains unsigned. The business case is currently with Te Whatu Ora -Southern Management Team and following that it will enter an approvals cycle.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1 NZD | +5.26% | +5.26% | -14.53% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.53% | 49.56M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.87% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- PEB Stock
- News Pacific Edge Limited
- Pacific Edge Limited Completes a Commercial Agreement with Te Whatu Ora Southern